Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer.

Journal: Frontiers in oncology
Published Date: Dec 20, 2024

Abstract

BACKGROUND/AIMS: It was recently reported that a higher concentration of the bacterially produced metabolite indole 3-acetate (3-IAA) in blood was linked to a better response to chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Here, we aimed to extend these observations to patients diagnosed with non-metastatic PDAC.

Authors

  • Peder R Braadland
    Research Institute of Internal Medicine and Norwegian PSC Research Center, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway.
  • Ingvild Farnes
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Elin H Kure
    Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Sheraz Yaqub
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Adrian McCann
    BEVITAL AS, Bergen, Norway.
  • Per M Ueland
    BEVITAL AS, Bergen, Norway.
  • Knut Jørgen Labori
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Johannes R Hov
    Research Institute of Internal Medicine and Norwegian PSC Research Center, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals